L-Dopa

Type: Keyphrase
Name: L-Dopa
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Adamas Pharmaceuticals Director William W. Ericson Acquires 300,000 Shares (ADMS)

Adamas Pharmaceuticals (NASDAQ:ADMS) Director William W. Ericson acquired 300,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 15th. The shares were purchased at an average cost of $16.00 per share, for a total transaction ... [Published American Banking News - Forex - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Top 10 Things You Didn’t Know about Brookhaven National Laboratory

This article is part of the Energy.gov series highlighting the “ Top Things You Didn’t Know About… ” Be sure to check back for more entries soon.Founded on the former site of the U.S. Army’s Camp Upton in New York in 1947, the Energy Department’s  Brookhaven ... [Published Breaking Energy online - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 2 reports

Adamas Pharmaceuticals Announces Closing of Its Initial Public Offering

PR NewswireEMERYVILLE, Calif., April 15, 2014EMERYVILLE, Calif.Credit Suisse and Piper JaffrayA registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on April 9, 2014.The offering was ... [Published Digital Journal - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Impax believes manufacturing issues are fixed

Drug developer seeks approval for Rytary; first app was sidelined by plant problemsShareToolsImpax Laboratories ($IPXL) had its future sidelined by manufacturing problems that set off a domino effect. The issues kept the FDA from considering its application ... [Published FiercePharmaManufacturing - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 1 reports

Domain Therapeutics Continues Program To Alter Course Of Parkinson's Disease With Renewed Support By The Michael J. Fox Foundation

– Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces the receipt of a second grant of 230 000 dollars (USD) from The Michael ... [Published BioSpace - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Newron and Zambon seek marketing approval for Parkinson's drug from Swissmedic

Newron Pharmaceuticals S.p.A., an R&D company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company, have announced the submission of the application for authorization for safinamide to Swissmedic. The submission ... [Published Individual.com - Apr 14 2014]
First reported Apr 12 2014 - Updated Apr 12 2014 - 1 reports

Herbal Treatment For Lost Penile Sensitivity And No Erection Due To Regular Masturbation

)Pressbox (Press Release) -Penile sensitivity or lack of penile sensation is faced by 85% of all men. Although older men are at higher risk of developing it men less than 30 years may also experience loss of sensation. The friction caused by regular masturbation ... [Published Pressbox.co.uk - Apr 12 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Global parkinson's disease market forecast to decline to U$2.9Bn by 2019

- Parkinson's Disease Therapeutics Market to 2019 - a new market research report on companiesandmarkets.comImpact of patent expiration unlikely to be diminished by new market entrants. Due to upcoming patent expirations for four high-profile drugs, the ... [Published PR inside - Apr 11 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 2 reports

Research and Markets: Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jjt9xv/parkinsons) has announced the addition of the "Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management" ... [Published Business Wire Professional Services News - Apr 11 2014]
Entities: Therapeutics, Market, L-Dopa
First reported Apr 10 2014 - Updated Apr 11 2014 - 4 reports

AbbVie announces availability of new advanced Parkinson's treatment in Canada

AbbVie has announced that a new treatment called Duodopa (levodopa/carbidopa intestinal gel) is now available to Canadians with advanced Parkinson's disease. ... [Published PBR - News - Apr 11 2014]
Entities: AbbVie Inc, Canada, L-Dopa
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Gene, stem cell therapies trials underway for Parkinson's, but not in Mumbai

illustration by: Ravi JadhavStem cells and gene hold promising treatment options for Parkinson's Disease, say doctors across the globe, including those in Mumbai.Eleven trials to test stem cell and gene therapies for treating the disease are currently ... [Published DNA India - Apr 11 2014]
Entities: Stem Cell, Dopamine, Mumbai
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Adamas Pharma wobble after IPO prices at $16 per share, at low end of expected range

NEW YORK, N.Y. - Shares of Adamas Pharmaceuticals wavered Thursday after the drug developer's initial public offering raised $48 million.The offering of 3 million shares priced at $16 each, the low end of an expected range of $16 to $18.The stock rose ... [Published Prince George Citizen - Apr 10 2014]

Quotes

...covers the indications "safinamide as add-on therapy to a stable dose of a single dopamine agonist" in early Parkinson's disease patients and "safinamide as add-on therapy to levodopa alone or in combination with other Parkinson's disease treatments" in mid-to late stage Parkinson's disease pa-tients. The submission was made by Zambon, who will be the Authorization holder
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jjt9xv/parkinsons) has announced the addition of the "Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management" report to their offering. The global PD market is anticipated to decline from $3.4 billion in 2012 to $2...
"Drugs such as L-dopa can, for a time, manage symptoms of Parkinson's disease, but as the disease worsens, tremors give way to immobility and, in some cases, to dementia . Even with good treatment, the disease marches on" says Ted Dawson, M D , Ph D , professor of neurology and director of the Johns Hopkins Institute for Cell Engineering
Currently, neuro-augmentative therapies, such as usage of drugs or deep brain stimulation DBS), are being used to treat Parkinson's Disease. "The future holds hope for neuro-restorative therapies like that of stem cells or gene infusion. Stem cells are the very primary kind of cells which can take on the function of any body part's cells after their infusion with that body part. It (the treatment) involves restoration of brain function to normal. In the next five to seven years, this may pave the way for the future" said Dr Paresh Doshi, neurologist at Jaslok Hospital on Peddar Road

More Content

All (125) | News (113) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Adamas Pharmaceuticals Director William W. Eric... [Published American Banking News - Forex - Apr 16 2014]
Top 10 Things You Didn’t Know about Brookhaven ... [Published Breaking Energy online - Apr 15 2014]
Pigment Production on L-Tryptophan Medium by Cr... [Published PLoS medicine - Apr 15 2014]
Adamas Pharmaceuticals Announces Closing of Its... [Published Digital Journal - Apr 15 2014]
Adamas Pharmaceuticals Announces Closing of Its... [Published Michigan Live - Apr 15 2014]
Impax believes manufacturing issues are fixed [Published FiercePharmaManufacturing - Apr 15 2014]
Parkinson’s Drug Rytary (Carbidopa/Levodopa) Re... [Published P&T Community - Apr 14 2014]
Domain Therapeutics Continues Program To Alter ... [Published BioSpace - Apr 14 2014]
Newron and Zambon seek marketing approval for P... [Published Individual.com - Apr 14 2014]
Herbal Treatment For Lost Penile Sensitivity An... [Published Pressbox.co.uk - Apr 12 2014]
DBS for Dystonia [Published Texomashomepage.com - Apr 11 2014]
Global parkinson's disease market forecast to d... [Published PR inside - Apr 11 2014]
Research and Markets: Parkinson's Disease Thera... [Published Business Wire Professional Services News - Apr 11 2014]
Research and Markets: Parkinson's Disease Thera... [Published Business Wire Health News - Apr 11 2014]
AbbVie announces availability of new advanced P... [Published PBR - News - Apr 11 2014]
Researchers identify biological process that ap... [Published News-Medical.Net - Apr 11 2014]
Parkinson’s disease could soon be history post ... [Published TruthDive - Apr 11 2014]
Clinical Review - Stroke [Published GP Online - Apr 11 2014]
Gene, stem cell therapies trials underway for P... [Published DNA India - Apr 11 2014]
AbbVie Announces Availability of New Advanced P... [Published Big News Network - Apr 10 2014]
Researchers identify biological process that a... [Published FOXNews.com - Apr 10 2014]
Getting to the root of Parkinson's disease [Published EurekAlert! - Apr 10 2014]
Adamas Pharma wobble after IPO prices at $16 pe... [Published Prince George Citizen - Apr 10 2014]
AbbVie's New Advanced Parkinson's Treatment Ava... [Published Drug Discovery and Development - Apr 10 2014]
AbbVie Announces Availability of New Advanced P... [Published Canada NewsWire - Apr 10 2014]
HealthWACH: D-B-S for Dystonia [Published WACH - Apr 10 2014]
Adamas Pharmaceuticals Announces Pricing Of Its... [Published PR Newswire - Apr 10 2014]
Adamas Pharmaceuticals Announces Pricing Of Its... [Published 4 Traders - Apr 09 2014]
DBS for Dystonia [Published My Sun Coast - Apr 09 2014]
Still Several Reasons To Remain Long Amarantus [Published Seeking Alpha - Apr 09 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Research and Markets: Parkinson's Disease Thera... [Published Business Wire Professional Services News - Apr 11 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jjt9xv/parkinsons) has announced the addition of the "Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management" ...
Research and Markets: Parkinson's Disease Thera... [Published Business Wire Health News - Apr 11 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jjt9xv/parkinsons) has announced the addition of the "Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management" ...
AbbVie announces availability of new advanced P... [Published PBR - News - Apr 11 2014]
AbbVie has announced that a new treatment called Duodopa (levodopa/carbidopa intestinal gel) is now available to Canadians with advanced Parkinson's disease. ...
Novel Formulation of Levodopa May Ease Parkinso... [Published MedlinePlus Health News - Mar 26 2014]
Source: Parkinson's Disease FoundationRelated MedlinePlus Page: Parkinson's Disease ...
Foundation Venture Capital Group appoints senio... [Published PE Hub Blog - Mar 20 2014]
Michael A. Wiley has joined Foundation Venture Capital Group , an affiliate of New Jersey Health Foundation , as the senior director of ventures and commercialization. Prior to joining FVCG, Wiley worked at the New Jersey Economic Development Authority ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.